New Gene Target Could Improve Cholesterol Without Harming the Liver

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.

9:38 AM

Author | Haley Otman

image of drawing of gene in blue ink on lined paper with lab note written on bottom right
Image by Stephanie King.

Medications to improve cholesterol and reduce cardiovascular risk factors can also put some patients at a higher risk for fatty liver disease or liver damage.

A new study from an international team of researchers points to a few genes as possible future targets to address cardiovascular risk without affecting the liver or causing other metabolic disorders.

"We know that some genes/proteins cause your cholesterol to either clog up your arteries or clog up your liver. We wanted to find genes that help people avoid it all: heart disease, diabetes and liver disease," explains co-corresponding author Cristen Willer, Ph.D., an associate professor of internal medicine, human genetics and computational medicine and bioinformatics, from the Michigan Medicine Frankel Cardiovascular Center.

Willer and colleagues identified 76 notable variants with potential, 11 of which were previously unreported. She says one in particular, known as ZNF529, was particularly interesting. People missing one copy of that gene had lower LDL cholesterol measures.

When the researchers in Y. Eugene Chen's Frankel CVC lab examined the gene in human liver cells, it had the same effect as a popular class of cholesterol-lowering drugs, PCSK9 inhibitors, that upregulate or activate the LDL receptor.

The researchers suggest future research to investigate inhibiting ZNF529. They also note this gene does not exist in mice, which limits the ability to study this gene in mice, but also suggests that mammals can survive without this gene.

"Understanding genes and genetic variants impacting the risk of CVD in the context of their biological roles will allow better choices for drug targets that will be more effective at preventing and treating disease, with fewer side effects," says co-corresponding author Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry.

Paper cited: "Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease." Nature Communications. DOI: 10.1038/s41467-020-20086-3

More Articles About: Lab Notes Heart Disease Risk Factors Nonalcoholic fatty liver disease (NAFLD) Genetics Metabolism, Endocrinology & Diabetes Drug Discovery Cardiovascular: Preventive Cardiology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories A family discussing their family's medical history at Thanksgiving
Health Lab
Why you need to discuss your family health history at Thanksgiving
The holidays are a great time to discuss your family's medical history. Learn the importance of discussing your family's health history & how to bring it up.
finger pointing at person
Health Lab
Examining mental health and reducing stigma in diabetes
Research at Michigan Medicine has been working to improve the psychosocial concerns related to diabetes, which often pose issues for people living with the condition
mom child and doctor smiling by tree
Health Lab
A diabetes device that makes a lot of “Sense”
Living with diabetes at such a young age comes with challenges, but those challenges have inspired Jackson, now 8 years old, to come up with ways for people like him to live a little easier with a new device called "SensePod".
cells in green and purple and black background under microscope
Health Lab
Tiny model organs detect liver toxicity of new drugs
A University of Michigan-led study provided evidence of the efficacy of a new drug-induced liver injury screening platform using human liver organoids, or tiny 3D models of organs developed from patients’ stem cells that grow in petri dishes.
surgeons in OR with blue and teal scrubs with screen on and patient under teal sheet
Health Lab
Treating heart valve disease: What are your options?
Michigan Medicine’s head of cardiac surgery, Gorav Ailawadi, M.D, M.B.A., answers questions about different treatment options for heart valve disease.
red lines with heart through it beige background
Health Lab
Research finds potential target for cardiovascular disease in diabetes
University of Michigan researchers found that the overproduction of neutrophil extracellular traps is an important contributing factor to vascular dysfunction in diabetes.